CEBPA and cancer: Although this observation was not validated across the pan-cancer cohort (Figure 5A), in the small cohort of TIMEPOINT patients with intrahepatic cholangiocarcinoma, patients who demonstrated CEBPA upregulation 24 h after MTL-CEBPA treatment demonstrated disease stabilization post combination treatment compared to those with no upregulation of CEBPA (Figure 4B).